Ringer`s Injection

Country: Armenja

Lingwa: Ingliż

Sors: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Ingredjent attiv:

sodium chloride, potassium chloride, calcium chloride

Disponibbli minn:

Liqvor CJSC

INN (Isem Internazzjonali):

sodium chloride, potassium chloride, calcium chloride

Dożaġġ:

8,6mg/ml+0,3mg/ml+0,49mg/ml

Għamla farmaċewtika:

solution for infusion

Tip ta 'preskrizzjoni:

Prescription

Karatteristiċi tal-prodott

1
SUMMURY OF PRODUCT CHARACTERISTICS
1.
NAME OF MEDICINAL PRODUCT: Ringer`s injection INN: Sodium chloride, Potassium chloride, Calcium chloride
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Sodium chloride
- 8,6 g
(Eur. Ph., Monograph 0193)
Potassium chloride
- 0,3 g
(Eur. Ph., Monograph 0185)
Calcium chloride 6Н
2
О
- 0,49 g
(Eur. Ph., Monograph 0707)
Water for injection
- до 1 L
(Eur. Ph., Monograph 0169) DESCRIPTION: Clear colorless solution.
3.
PHARMACEUTICAL FORM: solution for infusion
4.
CLINICAL PARTICULARS
4.1 INDICATIONS FOR USE
Dehydration of different genesis, hyponatremia, during and after
operations to
maintain the volume of plasma, in acute circulatory disorders,
accompanied by
dehydration.
4.2 DOSAGE AND ADMINISTRATION
Ringer`s injection must be administrated by intravenous at a rate
infusion at a rate
of 4 - 10 ml / kg / hour (up to 3 liters per day).
The dosage is individual, depending on the deficiency of water and
electrolytes.
Prolonged administration of large doses of the drug is preferably to
conduct under
the control of laboratory tests.
4.3 CONTRAINDICATIONS
Hypersensitivity to the drug components, decompensated heart failure,
pulmonary
edema, brain edema, oliguria, anuria, acidosis, hypervolemia,
hyperchloremia,
2
hypercalcemia, hypernatremia, concomitant therapy with
corticosteroids.
With caution - heart failure, hypertension, hepatic or renal
dysfunction.
4.4 SPECIAL WARNING
At a long-term treatment it is necessary to control the plasma
electrolytes and
water balance.
Due to high levels of chloride ions do not recommend the long-term use
of the
drug.
4.5 DRUG INTERACTION
It is possible the increasing of the sodium retention in the organism
at simultaneous
use of the following drugs: non-steroidal anti-inflammatory drugs,
androgens,
anabolic hormones, estrogens, corticotropin, mineralocorticoids,
vasodilators or
ganglionic blockers.
The
simultaneous
use
with
potassium-sparing
diuretics,
ACE
inhibitors
and
potassium therapy increases the risk of hyperkalemia.
The combination with cardi